Chemically Defined vs. Protein-Free CHO Medium: Why the Difference Matters for GMP

Chemically Defined vs. Protein-Free CHO Medium: What GMP Manufacturers Need to Know | SeamlessBio

The terms are often used interchangeably. They should not be. For manufacturers of therapeutic proteins in CHO cells, confusing chemically defined with protein-free can create serious problems at process validation — and occasionally in regulatory submissions.

Here is a clear breakdown of what each term means and why it matters.

Chemically Defined: Every Component Is Known

A chemically defined (CD) medium contains only components whose chemical identity and concentration are fully specified. No undefined biological extracts, no animal-derived hydrolysates, no serum fractions.

This does not mean the medium is simple. Modern chemically defined CHO media contain 50–80 individual components: amino acids, vitamins, trace elements, lipids, insulin or insulin-like growth factor alternatives, transferrin or recombinant transferrin substitutes, and buffering systems.

The key regulatory benefit: because every component is defined, the medium can be fully documented in a Drug Master File or process description without reference to variable biological sources.

Protein-Free: A Subset of Chemically Defined

A protein-free medium goes further. It eliminates all proteins from the formulation — including recombinant versions of insulin, transferrin and albumin that appear in many chemically defined media.

Why does this matter? Proteins in the medium complicate downstream purification. Any residual protein from the medium becomes a potential impurity in the product stream. For mAb manufacturing where protein A affinity purification is standard, medium-derived proteins that bind to the column or co-purify with the product create additional validation burden.

Protein-free formulations avoid this entirely. They substitute recombinant proteins with small-molecule alternatives: insulin mimetics, iron chelators in place of transferrin, no albumin.

Animal-Origin-Free: The Third Term

A third designation — animal-origin-free (AOF) — is increasingly required in regulatory submissions. An AOF medium contains no components derived from animal sources at any point in the manufacturing chain, including excipients, processing aids and raw material sourcing.

A medium can be chemically defined but not AOF if, for example, it contains recombinant insulin produced in a CHO cell line using animal-derived media components during manufacturing of the insulin itself. Full AOF status requires supplier-level documentation.

The GMP Implications

Designation	Defined Components	Proteins Present	Animal-Origin Risk	GMP-Dokumentation
Serumfrei	Teilweise	Ja	Reduced	Standard lot testing
Chemisch definiert	Full	Often yes	Niedrig	Full component documentation
Protein-free	Full	Nein	Niedrig	Simplified downstream
frei von tierischen Bestandteilen	Full	Optional	Keine	AOF declarations required

For Phase I/II clinical manufacturing, a chemically defined medium is typically sufficient. For pivotal trials and commercial manufacturing, protein-free and AOF status become increasingly expected by EMA and FDA reviewers.

What to Ask Your Supplier

Before committing to a CHO medium for GMP manufacturing, request:

1. Full component list with CAS numbers
2. Certificate of compliance for animal-origin-free status
3. Statement on recombinant protein sourcing (how was the rInsulin or rTransferrin manufactured?)
4. GMP-grade batch documentation: CoA, CoO, full traceability
5. ISO 13485 certification for the manufacturing site

→ SeamlessBio supplies chemically defined, protein-free and animal-origin-free CHO media under ISO 13485 with GMP-grade batch documentation: Serumfreie Medien für CHO-Zellen